CA2001936A1 - Methodes et composes pour traiter l'hypertension oculaire a l'aide de steroides angiostatiques - Google Patents

Methodes et composes pour traiter l'hypertension oculaire a l'aide de steroides angiostatiques

Info

Publication number
CA2001936A1
CA2001936A1 CA2001936A CA2001936A CA2001936A1 CA 2001936 A1 CA2001936 A1 CA 2001936A1 CA 2001936 A CA2001936 A CA 2001936A CA 2001936 A CA2001936 A CA 2001936A CA 2001936 A1 CA2001936 A1 CA 2001936A1
Authority
CA
Canada
Prior art keywords
ocular hypertension
methods
angiostatic steroids
compositions
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2001936A
Other languages
English (en)
Other versions
CA2001936C (fr
Inventor
Abbot F. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2001936A1 publication Critical patent/CA2001936A1/fr
Application granted granted Critical
Publication of CA2001936C publication Critical patent/CA2001936C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA002001936A 1988-10-31 1989-10-31 Methodes et composes pour traiter l'hypertension oculaire a l'aide de steroides angiostatiques Expired - Lifetime CA2001936C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264,918 1988-10-31
US07/264,918 US4876250A (en) 1988-10-31 1988-10-31 Methods for controlling ocular hypertension with angiostatic steroids

Publications (2)

Publication Number Publication Date
CA2001936A1 true CA2001936A1 (fr) 1990-04-30
CA2001936C CA2001936C (fr) 2000-04-25

Family

ID=23008183

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002001936A Expired - Lifetime CA2001936C (fr) 1988-10-31 1989-10-31 Methodes et composes pour traiter l'hypertension oculaire a l'aide de steroides angiostatiques

Country Status (11)

Country Link
US (1) US4876250A (fr)
EP (1) EP0371617B1 (fr)
JP (1) JP3049504B2 (fr)
KR (1) KR900005984A (fr)
AT (1) ATE106731T1 (fr)
AU (1) AU628874B2 (fr)
CA (1) CA2001936C (fr)
DE (1) DE68915958T2 (fr)
DK (1) DK172058B1 (fr)
NZ (1) NZ231086A (fr)
PT (1) PT92123B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
EP0581803A4 (fr) * 1991-03-21 1994-03-18 Sinai School Medicine Compositions et procedes de traitement de toute une variete de troubles a l'aide d'etianate et de ses agonistes.
US5239094A (en) * 1991-04-12 1993-08-24 Brigham And Women's Hospital Tetrahydro-S-21-Br
CA2111699A1 (fr) * 1991-06-18 1992-12-23 Gerard Schwadrohn Compositions pharmaceutiques anti-glaucomateuses et leur procede d'obtention
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
ATE232540T1 (de) * 1991-11-22 2003-02-15 Alcon Lab Inc Angiostatische steroide
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
CA2237898A1 (fr) * 1995-11-17 1997-05-29 Louis Desantis Jr. Therapie combinee pour le traitement du glaucome
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
WO2001041781A2 (fr) * 1999-12-09 2001-06-14 Alcon Universal Ltd. Inhibiteurs de proteine id pour le traitement de maladies oculaires
ES2295169T3 (es) 2000-05-19 2008-04-16 Michael S. Berlin Sistema de administracion de laser y procedimiento de uso para el ojo.
US8679089B2 (en) * 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
CA2428799A1 (fr) * 2000-11-16 2002-05-23 Alcon Manufacturing, Ltd. Therapie combinee abaissant et regulant la tension intraoculaire
CN1684701B (zh) 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
ES2244361T1 (es) * 2002-08-05 2005-12-16 Alcon, Inc. Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad.
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
JP2011513002A (ja) 2008-03-05 2011-04-28 イバンティス インコーポレイテッド 緑内障を治療する方法及び器具
ES2744879T3 (es) 2008-05-28 2020-02-26 Reveragen Biopharma Inc Moduladores esteroideos no hormonales de NF-kappaB para el tratamiento de enfermedades
AU2010271218B2 (en) 2009-07-09 2017-02-02 Alcon Inc. Ocular implants and methods for delivering ocular implants into the eye
US9693899B2 (en) 2009-07-09 2017-07-04 Ivantis, Inc. Single operator device for delivering an ocular implant
WO2011127048A2 (fr) 2010-04-05 2011-10-13 Validus Biopharma MODULATEURS STÉROÏDES NON HORMONAUX DE NF-ĸB POUR LE TRAITEMENT DE MALADIES
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014085450A1 (fr) 2012-11-28 2014-06-05 Ivantis, Inc. Appareil de délivrance d'implants oculaires dans une chambre antérieure de l'œil
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
JP6837475B2 (ja) 2015-08-14 2021-03-03 イバンティス インコーポレイテッド 圧力センサを備えた眼用インプラントおよび送達システム
WO2017106517A1 (fr) 2015-12-15 2017-06-22 Ivantis, Inc. Implant vasculaire et système de pose
JP6990321B2 (ja) 2018-02-22 2022-01-12 イバンティス インコーポレイテッド 眼用インプラントおよび送達システム
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US11540940B2 (en) 2021-01-11 2023-01-03 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
WO1986002189A1 (fr) * 1984-10-05 1986-04-10 Olympus Optical Co., Ltd. Tete magnetique composee
EP0221705A1 (fr) * 1985-10-23 1987-05-13 The Upjohn Company Tétrahydro-stéroides à activité angiostatique
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids

Also Published As

Publication number Publication date
DK542989A (da) 1990-05-01
DE68915958T2 (de) 1994-09-22
CA2001936C (fr) 2000-04-25
ATE106731T1 (de) 1994-06-15
JPH02196722A (ja) 1990-08-03
AU4370289A (en) 1990-05-03
EP0371617B1 (fr) 1994-06-08
US4876250A (en) 1989-10-24
PT92123A (pt) 1990-05-31
AU628874B2 (en) 1992-09-24
KR900005984A (ko) 1990-05-07
EP0371617A2 (fr) 1990-06-06
NZ231086A (en) 1991-07-26
DK542989D0 (da) 1989-10-31
DE68915958D1 (de) 1994-07-14
DK172058B1 (da) 1997-10-06
EP0371617A3 (fr) 1992-01-22
JP3049504B2 (ja) 2000-06-05
PT92123B (pt) 1995-06-30

Similar Documents

Publication Publication Date Title
CA2001936A1 (fr) Methodes et composes pour traiter l'hypertension oculaire a l'aide de steroides angiostatiques
CA2123405A1 (fr) Steroides angiostatiques
CA2315829A1 (fr) Agents angiostatiques et compositions permettant de lutter contre l'hypertension intra-oculaire
AU649605B2 (en) Retinal, derivatives and their therapeutic use
CA2129287A1 (fr) Emploi du cloprostenol, du fluprostenol et de leurs analogues pour le traitement du glaucome et de l'hypertension oculaire
CA2087420A1 (fr) Composition pharmaceutique ophthalmique contenant de la n-acetyl-cisteine et de l'alcool polyvinylique
CA2083179A1 (fr) Isoxazole-4-carboxamides et hydroxyalkylidenecyanoacetamides; produits pharmaceutiques a base de ces composes et leur utilisation
NZ241211A (en) 16alpha,17alpha-alkylidenedioxy-11b,21-dihydroxypregan -4-ene-3,20-dione derivatives substituted by halogen in either or both of the 6alpha- or the 9alpha- position; pharmaceutical compositions, methods of preparation and treatment
AU7317387A (en) Use of tetrahydrocortisol in glaucoma therapy
WO1998039293A3 (fr) 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome
AU4263789A (en) Antimalarial compositions and methods of treatment using quinidine, artemisinine and its derivatives
CA2347863A1 (fr) Traitement des affections de la retine
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
CA2235951A1 (fr) Nouveaux emplois du ctla-8 de mammifere et reactifs associes
DE3267670D1 (en) Pharmaceutical preparation for treating glaucoma and ocular hypertension
CA2139781A1 (fr) Composition ophtalmique contenant un semi-hydrate de (s)-timolol
AU641157B2 (en) 2-imino-thiadiazoline-5-sulphonamides and their use in the treatment of glaucoma
CA2149766A1 (fr) Compositions a base de flunisolide pour application rectale servant au traitement des troubles inflammatoires de l'intestin
AU1294195A (en) Compositions and methods for the treatment of dry eyes and other ocular disorders
AU627874B2 (en) Amino-benzenesulfonamides in the treatment of glaucoma
CA2140345A1 (fr) Composes anti-inflammatoires a usage ophthalmique
AU625096C (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
AU1243188A (en) Block copolymer compositions and process for the preparation thereof
HK1111636A1 (en) Fluprostenol isopropyl ester for use in the treatment of glaucoma and ocular hypertension

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry
MKEX Expiry

Effective date: 20091031